Bruton's tyrosine kinase inhibitors and cardiovascular risk: a meta-analysis
Doctors now have clearer data showing that a commonly used blood cancer treatment modestly increases heart attack and stroke risk, helping them weigh benefits against cardiovascular safety.
This systematic review and meta-analysis of 17 Phase 3 RCTs (n=6,799; predominantly ibrutinib) quantified ischaemic cardiovascular risk associated with BTK inhibitor therapy in B-cell malignancies, finding a statistically significant 66% elevation in non-fatal MACE including myocardial ischaemia and stroke. The finding has immediate clinical relevance given the widespread use of ibrutinib, acalabrutinib, and zanubrutinib in CLL, MCL, and other B-cell malignancies, and adds ischaemic risk to the established BTKi cardiovascular risk profile (atrial fibrillation, hypertension, bleeding).
What the study was
- Study design
- systematic_review_meta_analysis
- Population
- B-cell malignancy patients (CLL, MCL, other B-cell NHL) receiving BTK inhibitors across 17 Phase 3 RCTs
- Sample size
- 6799
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- European Heart Journal
Why it surfaced
Top-tier cardio-oncology safety signal in Eur Heart J based on rigorous meta-analysis of Phase 3 RCT data; BTKi are prescribed to hundreds of thousands of patients globally; clinically actionable recommendation to monitor for ischaemic events; substantial heterogeneity (I²=70%) suggests drug-class differences warranting per-agent analysis.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.